SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?


To: Larry L who wrote (190)5/20/1998 1:06:00 AM
From: Miljenko Zuanic  Respond to of 550
 
From poster presentation:

SU 5416 do have two responded (PR)and one SD patients (KS and two colorectal cancer with 5+ cycle on drugs ).

Drug is fairly well tolerated, but some issue on drug pharmacokinetic are not completely clear. Company will in KS escalation doses PI/II trial (initial dose is 36 mg) tried to clear PK (for future dose/regimen designee) and access drug efficiency as anti-angiogenesis.

mz